Organization
Whitechurch, United Kingdom
1 abstract
Abstract
Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (DEP CTX) in patients with advanced solid cancers in a phase 1/2 trial (P1/2).Org: King's College London, Imperial College, University College London Cancer Institute, University College London Hospital NHS Trust and Great Ormond Street Hospital, Kinghorn Cancer Centre,